ClinicalTrials.gg
Enrolling by invitationNCT06542939Updated Oct 1, 2026

Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)

An interventional study of Integrated CHW Intervention and CHW Session 1 Only in Diabetes Mellitus Type II and Hypertension, sponsored by NYU Langone Health. Enrolling by invitation at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

Updated Oct 1, 2026Eligibility revisedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · NYU Langone Health.

Planned enrollment
2nd of 23
450 · median 100
Started
2024
with 2 others
No phase
20 of 25
6 open now
Registered
23rd of 25
by date

Among the 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 20 with no phase, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health, or all of them as a file.
02

Study summary

The purpose of this study is to test the effectiveness and implementation process of a culturally and contextually tailored telehealth-based community health worker (CHW) led coaching intervention for hypertension control among South Asian patients with co-morbid Diabetes Mellitus type II (DMII) and hypertension. The primary aims are to test the effectiveness of a CHW-led telehealth intervention compared to usual care, and using Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) and Consolidated Framework for Implementation Research (CFIR), examine the reach, adoption, fidelity, and maintenance of the intervention within clinical and community settings.

03

Conditions studied

  • Diabetes Mellitus Type II
  • Hypertension
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • identified as of South Asian ethnicity
  • at least 21 years of age
  • a diagnosis of diabetes
  • a diagnosis of hypertension
  • an uncontrolled BP reading (>130/80mmHg) in the last 6 months

Exclusion criteria

Exclusion Criteria:

  • Under the age of 21
  • Women who are pregnant at the time of screening
  • Type 1 diabetes or diabetes secondary to other conditions (e.g., -induced, pancreatic insufficiency, or chemotherapy-induced)
  • Inability to perform unsupervised physical activity
  • or life-threatening illness with of \<5 years
  • Diagnosed cognitive deficits or limited decision-making capacity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Community Health Workers (CHW) treatment group

    There is a 6-month intervention period immediately following recruitment. Participants enrolled in the intervention will complete 5 educational sessions and attend 2 one-on-one virtual meetings.

    Behavioral: Integrated CHW Intervention

  • Active comparator
    Control group

    The control participants will complete only the first educational session. The control arm will receive usual care from their primary care physician (PCP) during the first 12 months of data collection. After 12 months they will be invited to attend remaining group sessions.

    Behavioral: CHW Session 1 Only

Interventions

  • BehavioralIntegrated CHW Intervention

    Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.

  • BehavioralCHW Session 1 Only

    Participants will attend only the first group-based health education session on hypertension and diabetes management.

06

What researchers measure

Primary outcomes

  1. Percent of participants achieving BP control, defined as <130/80 mmHg

    The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) at six months.

    Time frame: Month 6

Secondary outcomes

  1. Percent of participants achieving BP control, defined as <130/80 mmHg

    The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) at twelve months.

    Time frame: Month 12

  2. Change from Baseline in hemoglobin A1c (HbA1c) levels at Month 6

    Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 6

  3. Change from Baseline in HbA1c levels at Month 12

    Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 12

  4. Change from Baseline in Body mass index (BMI) at Month 6

    Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 6

  5. Change from Baseline in BMI at Month 12

    Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 12

  6. Change from Baseline in Systolic blood pressure (SBP) at Month 6

    Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 6

  7. Change from Baseline in SBP at Month 12

    Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 12

  8. Change from Baseline in Diastolic blood pressure (DBP) at Month 6

    Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 6

  9. Change from Baseline in DBP at Month 12

    Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.

    Time frame: Baseline, Month 12

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: laura.wyatt@nyulangone.org . The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be provided access upon reasonable request. Requests should be directed to laura.wyatt@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2028, 38 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 38 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 7, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Emory University · Atlanta, United States
Oct 1, 2026
Eligibility
2 exclusion criteria edited, 2 added
What changed in the criteria
Exclusion criteria
  • EditedWomen who are pregnant at the time of screening
  • EditedType 1 diabetes or diabetes secondary to other conditions (e.g., steroid-induced, pancreatic insufficiency, or chemotherapy-induced)
  • AddedMalignancy or life-threatening illness with life expectancy of <5 years
  • AddedDiagnosed cognitive deficits or limited decision-making capacity
Oct 1, 2026
Title
Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension in Immigrant Populations (Phase II)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added
    Show site
    • Emory University · Atlanta, United States
    Eligibility 2 exclusion criteria edited, 2 added
    What changed in the criteria
    Exclusion criteria
    • EditedWomen who are pregnant at the time of screening
    • EditedType 1 diabetes or diabetes secondary to other conditions (e.g., steroid-induced, pancreatic insufficiency, or chemotherapy-induced)
    • AddedMalignancy or life-threatening illness with life expectancy of <5 years
    • AddedDiagnosed cognitive deficits or limited decision-making capacity
    Title Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension in Immigrant Populations (Phase II)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06542939
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Nov 11, 2024
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Nadia Islam, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion